Respiratory Motion, Inc. (RMI) is a new generation medical device company developing and commercializing the ExSpironTM. RMI’s goal is to cost-effectively improve the standard of care in respiration monitoring. Ventilation monitoring is increasingly recommended as oxygen saturation levels inadequately predict ventilatory distress.
The ExSpironTM is a noninvasive, continuous respiratory monitor which has received FDA clearance to graphically display lung volumes against time and report quantitative values of:
This valuable data, previously only available for intubated patients receiving mechanical ventilation, is now available noninvasively to assess respiratory function in a wide variety of patients.
Minute Ventilation is the best way to assess respiratory competence. This becomes especially important in patients receiving opioids, anesthetics or sedatives, who are more at risk for Respiratory Depression. While recent standards call for monitoring ventilation in all post operative patients receiving opioids, the elderly and obese populations may be at increased risk.
To find out more about our investment criteria and what we're looking for, please send us an email .
SEC Rules and the Startup World - The Latest
The world of equity fundraising has really changed since September 23, when the SEC rules lifting the ban on general solicitation became effective.